

What is the impact of HPV vaccination in the UK?

GARDASIL.9 **Human Papillomavirus** 9-valent Vaccine, Recombinant



(HPV) vaccination The Joint Committee for

The history of Human Papillomavirus

2019

2021

2022

recommended HPV immunisation programme for girls aged 12-13 years. A 'catch-up' campaign to immunise girls aged 13–18 years against HPV was instigated1 The aim was to reduce risk of cervical cancer caused by HPV

Vaccination and Immunisation

types 16 and 18, which were included in the bivalent vaccines at the time^{1,2}

attending sexual health services andHIV clinics became eligible for HPV vaccination¹ Eligible boys (eligibility for boys

include males born on or after

Men who had sex with men

(GBMSM) aged ≤45 years


1 September 2006) and girls aged between 14 and 25 years who missed their HPV vaccination in schools can receive the HPV vaccine in primary care, either opportunistically or when it is requested³ In 2022, genital warts first

17 years, respectively, compared to 2018⁹

episode rates were reduced by

almost 68% and 72% among girls

and heterosexual boys aged 15-



Expected to provide clear health benefits for vaccinated boys against HPV infection¹

aged 12-13 years¹


extended to include eligible boys

HPV vaccine changed from Gardasil® (HPV types 6, 11, 16 and 18) to the nine-valent

vaccine Gardasil® 9 (HPV types

6, 11, 16, 18, 31, 33, 45, 52

and 58)1,4,5







2014

2008





the national uptake of HPV vaccination in



In the UK during 2022, over HPV vaccine uptake in the UK 30% of girls and almost 40% declined since the start of the

2020-2021

76.6% of girls

71.0% of boys¹²




2019–2020

59.2% of girls

54.4% of boys¹¹

SARS-CoV-2 pandemic in early





Vaccination protects against

and diseases

69.6% of girls

62.4% of boys¹³

certain HPV-related cancers



Want to learn more? Click on the link below to access more resources on HPV including:

Clicking the link above will take you to a promotional MSD webpage

What is HPV and its associated risks?

How can you improve HPV vaccination uptake?

What strategies can GP practices implement to increase HPV vaccination rates?

women aged 20 to younger than 30 years old, across three different cohorts⁷ Gardasil® 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases:^{4,5}

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme Limited (Tel: 0208 154 8000). By clicking the above link, you will leave the MSD website and be taken to the MHRA website.

Improvement. GP letter on vaccination and immunisation changes for 2021/22. March 2021. Available at: https://www.england.nhs.uk/ wp-content/uploads/2021/03/B0434 Update-on-vaccination-and-immunisation-changes-for-202122-v4.pdf. Last accessed: November

2024. 4. Gardasil® 9 (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed). Summary of Product Characteristics (SPC) for GB.

*2021 observational study by Falcaro et al. This observational study used modelling data from a total of 13.7 million years of follow up of

Please refer to the Summary of Product Characteristics for further information prior to making any prescribing decisions.^{4,5}

• Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types

• Genital warts (Condyloma acuminata) caused by specific HPV types

References: 1. UK Health Security Agency. Human Papillomavirus (HPV): the green book, chapter 18a. March 2022. Available at: https:// www.gov.uk/government/publications/human-papillomavirus-hpv-the-green-book-chapter-18a. Last accessed: November 2024. 2. Cervarix® (Human Papillomavirus vaccine [Types 16, 18]) (Recombinant, adjuvanted, adsorbed). Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/cervarix. Last accessed: November 2024. 3. NHS England and NHS

Available at: https://www.emcpi.com/pi/32240. Last accessed: November 2024 5. Gardasil® 9 (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed). Summary of Product Characteristics (SPC) for NI. Available at: https://www.emcpi.com/pi/ni/496. Last accessed: November 2024. 6. UK Health Security Agency. Information on HPV vaccination: Available at: https://www.gov.uk/government/publications/ hpv-vaccine-vaccination-guide-leaflet/information-on-hpv-vaccination#:~:text=More%20than%20280%20million%20doses,10%20 million%20in%20the%20UK. Last accessed: November 2024. 7. Falcaro M, et al. Lancet. 2021; 389:2084–2092. 8. Public Health England. Surveillance of type-specific HPV in sexually active young females in England, to end 2018. January 2020. Available at: https://assets. publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/858872/hpr0220_HPV_2018.pdf. Last accessed: November 2024. 9. Public Health England. Sexually Transmitted Infections and Chlamydia Screening in England Report. 2022. Available at: https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables/sexually-transmitted-infections-andscreening-for-chlamydia-in-england-2022-report. Last accessed: November 2024. 10. Public Health England. Human papillomavirus (HPV) immunisation programme review: 2008 to 2014. March 2015. Available at: https://www.gov.uk/government/publications/humanpapillomavirus-hpv-immunisation-programme-review-2008-to-2014. Last accessed: November 2024. 11. UK Health Security Agency. Human papillomavirus (HPV) vaccine coverage estimates in England: 2019 to 2020. December 2021. Available at: https://assets.publishing. service.gov.uk/government/uploads/system/uploads/attachment_data/file/927694/hpr1920_HPV-vc.pdf. Last accessed: November 2024. 12. UK Health Security Agency. Human papillomavirus (HPV) vaccine coverage estimates in England: 2020 to 2021. December 2021. Available at: https://www.gov.uk/government/statistics/human-papillomavirus-hpv-vaccine-coverage-estimates. Last accessed: November 2024. 13. UK Health Security Agency. Human papillomavirus (HPV) vaccine coverage estimates in England: 2021 to 2022. December 2022. Available at: https://www.gov.uk/government/statistics/human-papillomavirus-hpv-vaccine-coverage-estimates-in-england-2021-to-2022. Last accessed: August 2023. 14. UKHSA Human papillomavirus (HPV) vaccination coverage in adolescents in England: 2022 to 2023. Human papillomavirus (HPV) vaccination coverage in adolescents in England: 2022 to 2023 - GOV.UK (www.gov.uk) Last accessed May 2024 Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom.

Registered in England No. 233687 © Merck Sharp & Dohme (UK) Limited 2024. All rights reserved. GB-GSL-00696 | November 2024

